Scapa Group, a diversified healthcare and industrial group, completed the acquisition of Systagenix Wound Mgt Manufacturing for £31m. “The Transaction marks a milestone in our healthcare journey from a material supplier to a global healthcare company. It bridges the final gaps in our value proposition in capabilities, services and footprint. The Gargrave facility will serve as our European centre of excellence with its state of the art manufacturing facility and significant innovation and development capability. Additionally, the Transaction will further strengthen our strategic relationship with Acelity by supporting its strategy for continued growth as the leading wound care company in the world," Heejae Chae, Scapa Group Group Chief Executive.